Showing 2841-2850 of 3844 results for "".
- ADAM Accepting Nominations for Practice Manager of the Yearhttps://practicaldermatology.com/news/adam-accepting-nominations-for-practice-manager-of-the-year/2458363/The Association of Dermatology Administrators and Managers is accepting nominations for its annual Practice Manager of the Year Award. Now in its fourth year, the Practice Manager of the Year Award recognizes the office professional who best demonstrates innovative thinking, ins
- Novan: SB414 Inhibited IL-17 in Psoriasis Mouse Modelhttps://practicaldermatology.com/news/novan-sb414-inhibited-il-17-in-psoriasis-mouse-model/2458374/Novan, Inc. has announced preclinical data showing that its nitric oxide-releasing product candidate SB414 significantly (p<0.05) reduced composite psoriasis scores, which consist of erythema and plaque scores, and pro-inflammatory cytokines, including interleukin-17, or IL-17, in a
- Novan: Phase 2b Data for SB204 Gel to be Presented at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/novan-phase-2b-data-for-sb204-gel-to-be-presented-at-fall-clinical-dermatology-conference/2458396/Results from Novan’s Phase 2b clinical trial to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne vulgaris will be presented at the 35th Anniversary Fall Clinical Dermatology Conference in Las Vegas. The presentation wil
- Biosim Update: Pfizer to Begin Shipping INFLECTRA in Late November 2016https://practicaldermatology.com/news/biosim-update-pfizer-to-begin-shipping-inflectra-in-late-november-2016/2458400/Pfizer Inc. will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE1 (infliximab) to wholesalers in the United States in late November 2016. INFLECTRA will be the first biosimilar mono
- Oral Nalbuphine®ER Performs Well in Phase 2 Trial of Prurigo Nodularishttps://practicaldermatology.com/news/oral-nalbuphineer-performs-well-in-from-phase-2-trial-in-prurigo-nodularis/2458403/Trevi Therapeutics, Inc.’s Oral Nalbuphine®ER reduced itch intensity and improved quality of life in prurigo nodularis patients, according to a Phase 2 Trial. Nalbuphine ER is an oral extended release mu receptor an
- At-Home Nail Fungus Treatment Now Available From iSkinProductshttps://practicaldermatology.com/news/at-home-nail-fungus-treatment-now-available-from-iskinproducts/2458415/Cure-Ex nail fungus laser treatment device is now available from online beauty retailer, iSkinProducts. The portable device can be used on fingernails or toenails and a user can use the Cure-Ex laser from the comfort of their own home, according to the company. The Cure-Ex nail fungus tre
- Novan, Inc. Launches IPO, Lists on NASDAQhttps://practicaldermatology.com/news/novan-inc-launches-ipo-lists-on-nasdaq/2458429/Novan, Inc. (the “Company” or “Novan”) today announced the pricing of the Company’s initial public offering of 4,100,000 shares of common stock at a price to the public of $11.00 per share. The common stock of Novan has been approved for listing on the NASDAQ Global
- Venus Concept Unveils Venus Freeze Plus for Non-Invasive Anti-Aging Treatmentshttps://practicaldermatology.com/news/venus-concept-unveils-venus-freeze-plus-for-non-invasive-anti-aging-treatments/2458432/Venus Concept's non-invasive anti-aging device, Venus Freeze Plus, is now available in the US. It is indicated for the treatment of moderate-to-severe facial wrinkles and rhytides, leading to the tightening of the skin, with no pain or downtime. Venus Freeze Plus works by using Venus
- Is Bigger Better? Group Practices Become the New Normhttps://practicaldermatology.com/news/group-practices-are-the-new-norm/2458438/Group physician practices are the new normal, and it seems that dermatologists were ahead of the consolidation curve, according to research in the September 2016 issue of Health Affairs. Researchers examined physician consolidation for both primary care provide
- Novan: First Patient Dosed in Phase 2 Anti-Fungal Programhttps://practicaldermatology.com/news/nolan-first-patient-dosed-in-phase-2-anti-fungal-program/2458492/The first patient has been dosed in Novan's clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as Trichophyton rubrum (“T. rubrum”). Novan is developing